Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Apr 30

PMID 33923045

Citations 9

Authors

Utsa Bhaduri

Giuseppe Merla

Affiliations

Soon will be listed here.

Abstract

Ubiquitination is a post-translational modification that has pivotal roles in protein degradation and diversified cellular processes, and for more than two decades it has been a subject of interest in the biotech or biopharmaceutical industry. Tripartite motif (TRIM) family proteins are known to have proven E3 ubiquitin ligase activities and are involved in a multitude of cellular and physiological events and pathophysiological conditions ranging from cancers to rare genetic disorders. Although in recent years many kinds of E3 ubiquitin ligases have emerged as the preferred choices of big pharma and biotech startups in the context of protein degradation and disease biology, from a surface overview it appears that TRIM E3 ubiquitin ligases are not very well recognized yet in the realm of drug discovery. This article will review some of the blockbuster scientific discoveries and technological innovations from the world of ubiquitination and E3 ubiquitin ligases that have impacted the biopharma community, from biotech colossuses to startups, and will attempt to evaluate the future of TRIM family proteins in the province of E3 ubiquitin ligase-based drug discovery.

Citing Articles

Proximity-Induced Pharmacology for Amyloid-Related Diseases.

Bertran-Mostazo A, Putriute G, Alvarez-Berbel I, Busquets M, Galdeano C, Espargaro A Cells. 2024; 13(5.

PMID: 38474412 PMC: 10930901. DOI: 10.3390/cells13050449.

Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase.

Hoegenauer K, An S, Axford J, Benander C, Bergsdorf C, Botsch J ACS Med Chem Lett. 2023; 14(12):1631-1639.

PMID: 38116426 PMC: 10726445. DOI: 10.1021/acsmedchemlett.3c00259.

Beta-Transducin Repeats-Containing Proteins as an Anticancer Target.

Kim D, Yi Y, Seong Y Cancers (Basel). 2023; 15(17).

PMID: 37686524 PMC: 10487276. DOI: 10.3390/cancers15174248.

UPS: Opportunities and challenges for gastric cancer treatment.

Yang H, Ai H, Zhang J, Ma J, Liu K, Li Z Front Oncol. 2023; 13:1140452.

PMID: 37077823 PMC: 10106573. DOI: 10.3389/fonc.2023.1140452.

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma.

Wu J, Chu E, Paul B, Kang Y Cancers (Basel). 2022; 14(21).

PMID: 36358696 PMC: 9657746. DOI: 10.3390/cancers14215272.

References

Appikonda S, Thakkar K, Barton M . Regulation of gene expression in human cancers by TRIM24. Drug Discov Today Technol. 2016; 19:57-63. DOI: 10.1016/j.ddtec.2016.05.001. View

Zhang C, Mukherjee S, Tucker-Burden C, Ross J, Chau M, Kong J . TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3. Mol Oncol. 2017; 11(3):280-294. PMC: 5332279. DOI: 10.1002/1878-0261.12034. View

Nicklas S, Hillje A, Okawa S, Rudolph I, Collmann F, van Wuellen T . A complex of the ubiquitin ligase TRIM32 and the deubiquitinase USP7 balances the level of c-Myc ubiquitination and thereby determines neural stem cell fate specification. Cell Death Differ. 2018; 26(4):728-740. PMC: 6460386. DOI: 10.1038/s41418-018-0144-1. View

Watanabe M, Hatakeyama S . TRIM proteins and diseases. J Biochem. 2017; 161(2):135-144. DOI: 10.1093/jb/mvw087. View

Hadjimichael C, Chanoumidou K, Nikolaou C, Klonizakis A, Theodosi G, Makatounakis T . Promyelocytic Leukemia Protein Is an Essential Regulator of Stem Cell Pluripotency and Somatic Cell Reprogramming. Stem Cell Reports. 2017; 8(5):1366-1378. PMC: 5425614. DOI: 10.1016/j.stemcr.2017.03.006. View

Loedige I, Filipowicz W . TRIM-NHL proteins take on miRNA regulation. Cell. 2009; 136(5):818-20. DOI: 10.1016/j.cell.2009.02.030. View

McAvera R, Crawford L . TIF1 Proteins in Genome Stability and Cancer. Cancers (Basel). 2020; 12(8). PMC: 7463590. DOI: 10.3390/cancers12082094. View

Hentze M, Castello A, Schwarzl T, Preiss T . A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018; 19(5):327-341. DOI: 10.1038/nrm.2017.130. View

Ambrozkiewicz M, Cuthill K, Harnett D, Kawabe H, Tarabykin V . Molecular Evolution, Neurodevelopmental Roles and Clinical Significance of HECT-Type UBE3 E3 Ubiquitin Ligases. Cells. 2020; 9(11). PMC: 7697756. DOI: 10.3390/cells9112455. View

10.

Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L . The tripartite motif family identifies cell compartments. EMBO J. 2001; 20(9):2140-51. PMC: 125245. DOI: 10.1093/emboj/20.9.2140. View

11.

Julio A, Backus K . New approaches to target RNA binding proteins. Curr Opin Chem Biol. 2021; 62:13-23. PMC: 8823266. DOI: 10.1016/j.cbpa.2020.12.006. View

12.

Groettrup M, Pelzer C, Schmidtke G, Hofmann K . Activating the ubiquitin family: UBA6 challenges the field. Trends Biochem Sci. 2008; 33(5):230-7. DOI: 10.1016/j.tibs.2008.01.005. View

13.

Remboutsika E, Lutz Y, Gansmuller A, Vonesch J, Losson R, Chambon P . The putative nuclear receptor mediator TIF1alpha is tightly associated with euchromatin. J Cell Sci. 1999; 112 ( Pt 11):1671-83. DOI: 10.1242/jcs.112.11.1671. View

14.

Schlesinger D, Goldstein G . Molecular conservation of 74 amino acid sequence of ubiquitin between cattle and man. Nature. 1975; 255(5507):423-4. DOI: 10.1038/255423a0. View

15.

Marzano F, Caratozzolo M, Pesole G, Sbisa E, Tullo A . TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance. Biomedicines. 2021; 9(3). PMC: 7997459. DOI: 10.3390/biomedicines9030241. View

16.

Ishida T, Ciulli A . E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. SLAS Discov. 2020; 26(4):484-502. PMC: 8013866. DOI: 10.1177/2472555220965528. View

17.

Tsai W, Wang Z, Yiu T, Akdemir K, Xia W, Winter S . TRIM24 links a non-canonical histone signature to breast cancer. Nature. 2010; 468(7326):927-32. PMC: 3058826. DOI: 10.1038/nature09542. View

18.

Kane R, Bross P, Farrell A, Pazdur R . Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003; 8(6):508-13. DOI: 10.1634/theoncologist.8-6-508. View

19.

Akutsu M, Dikic I, Bremm A . Ubiquitin chain diversity at a glance. J Cell Sci. 2016; 129(5):875-80. DOI: 10.1242/jcs.183954. View

20.

DAmico F, Mukhopadhyay R, Ovaa H, Mulder M . Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class. Chembiochem. 2021; 22(12):2011-2031. PMC: 8251876. DOI: 10.1002/cbic.202000787. View